文献速递艾滋病与性传播感染

HIV血清阳转后CXCR4嗜性病毒与CD4 T细胞下降的关系

CD4 T cell decline following HIV seroconversion in individuals with and without CXCR4-tropic virus.
PubMed 文献 · J Antimicrob Chemother · 2017-01-01

该研究基于CASCADE大型HIV血清阳转者队列协作,比较了血清阳转时携带X4/DM嗜性病毒与R5嗜性病毒患者的自发性CD4 T细胞演变。结果显示,血清阳转后30个月内,两组CD4下降斜率无显著差异,且启动抗逆转录病毒治疗的时间无统计学差异。

要点

  • 血清阳转时15%的患者携带X4/DM嗜性病毒。
  • X4/DM嗜性与R5嗜性病毒患者的CD4下降斜率无显著差异。
  • 两组启动联合抗逆转录病毒治疗的时间无统计学差异。

核心结论

  • 在血清阳转时携带X4/DM嗜性病毒的患者未显示以CD4 T细胞计数下降或启动联合ART时间估计的疾病进展风险增加。

研究设计与样本

  • 研究纳入CASCADE队列协作中血清阳转后随访至少2年的患者,从入组时冻存血浆样本测序HIV包膜基因,使用Geno2Pheno(假阳性率10%)确定嗜性,采用线性混合效应模型比较CD4动力学。

主要发现

  • 共1387例患者符合条件,血清阳转至入组中位时间1个月(范围0-3)。
  • 入组时202/1387(15%)携带X4/DM嗜性病毒。
  • 血清阳转后30个月内,CD4下降斜率根据HIV-1嗜性无显著差异。
  • 调整年龄、血清阳转年份和基线HIV病毒载量后,结果无显著变化。
  • 启动抗逆转录病毒治疗时间在R5组(20.76个月)与X4/DM组(22.86个月)间无统计学差异(logrank检验P=0.32)。

临床怎么用

  • 血清阳转时检测到X4/DM嗜性病毒不应单独作为加速启动ART的依据,仍需结合CD4计数和病毒载量等标准。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The natural clinical and immunological courses following HIV seroconversion with CXCR4-tropic or dual-mixed (X4/DM) viruses are controversial. We compared spontaneous immunological outcome in patients harbouring an X4/DM virus at the time of seroconversion with those harbouring a CCR5-tropic (R5) virus. METHODS: Data were included from patients participating in CASCADE, a large cohort collaboration of HIV seroconverters, with ≥2 years of follow-up since seroconversion. The HIV envelope gene was sequenced from frozen plasma samples collected at enrolment, and HIV tropism was determined using Geno2Pheno (false-positive rate 10%). The spontaneous CD4 T cell evolution was compared by modelling CD4 kinetics using linear mixed-effects models with random intercept and random slope. RESULTS: A total of 1387 patients were eligible. Median time between seroconversion and enrolment was 1 month (range 0-3). At enrolment, 202 of 1387 (15%) harboured an X4/DM-tropic virus. CD4 decrease slopes were not significantly different according to HIV-1 tropism during the first 30 months after seroconversion. No marked change in these results was found after adjusting for age, year of seroconversion and baseline HIV viral load. Time to antiretroviral treatment initiation was not statistically different between patients harbouring an R5 (20.76 months) and those harbouring an X4/DM-tropic virus (22.86 months, logrank test P = 0.32). Conclusions: In this large cohort collaboration, 15% of the patients harboured an X4/DM virus close to HIV seroconversion. Patients harbouring X4/DM-tropic viruses close to seroconversion did not have an increased risk of disease progression, estimated by the decline in CD4 T cell count or time to combined ART initiation.

来源:J Antimicrob Chemother,查看原文。版权归原作者所有。

引用

  1. Ghosn J, Bayan T, Meixenberger K, et al. CD4 T cell decline following HIV seroconversion in individuals with and without CXCR4-tropic virus. J Antimicrob Chemother. 2017. PMID: 29091208. doi:10.1093/jac/dkx247

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。